NFL BIOSCIENCES EO -03
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more
NFL BIOSCIENCES EO -03 (82F) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, NFL BIOSCIENCES EO -03 (82F) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NFL BIOSCIENCES EO -03 - Net Assets Trend (None–None)
This chart illustrates how NFL BIOSCIENCES EO -03's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NFL BIOSCIENCES EO -03 (None–None)
The table below shows the annual net assets of NFL BIOSCIENCES EO -03 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to NFL BIOSCIENCES EO -03's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
NFL BIOSCIENCES EO -03 Competitors by Market Cap
The table below lists competitors of NFL BIOSCIENCES EO -03 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Edgewater Wireless Systems Inc
PINK:KPIFF
|
$8.35 Million |
|
Vardhman Acrylics Limited
NSE:VARDHACRLC
|
$8.35 Million |
|
LFLRF
OTCQB:LFLRF
|
$8.35 Million |
|
Swvl Holdings Corp
NASDAQ:SWVL
|
$8.35 Million |
|
Britania PCL
BK:BRI
|
$8.35 Million |
|
Sino Logistics Corporation Public Company Limited
BK:SINO
|
$8.35 Million |
|
Aban Offshore Limited
NSE:ABAN
|
$8.35 Million |
|
Logicquest Technology Inc
PINK:LOGQ
|
$8.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NFL BIOSCIENCES EO -03's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares NFL BIOSCIENCES EO -03's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently NFL BIOSCIENCES EO -03 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares NFL BIOSCIENCES EO -03's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NFL BIOSCIENCES EO -03 (82F) | €- | N/A | N/A | $8.35 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |